637 related articles for article (PubMed ID: 26255220)
1. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
2. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
4. D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation.
Schoubben A; Vivani R; Paolantoni M; Perinelli DR; Gioiello A; Macchiarulo A; Ricci M
Eur J Pharm Sci; 2019 Mar; 130():54-64. PubMed ID: 30677523
[TBL] [Abstract][Full Text] [Related]
5. Capreomycin inhalable powders prepared with an innovative spray-drying technique.
Schoubben A; Giovagnoli S; Tiralti MC; Blasi P; Ricci M
Int J Pharm; 2014 Jul; 469(1):132-9. PubMed ID: 24747443
[TBL] [Abstract][Full Text] [Related]
6. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
7. Simple and scalable method for peptide inhalable powder production.
Schoubben A; Blasi P; Giovagnoli S; Ricci M; Rossi C
Eur J Pharm Sci; 2010 Jan; 39(1-3):53-8. PubMed ID: 19879945
[TBL] [Abstract][Full Text] [Related]
8. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
You Y; Zhao M; Liu G; Tang X
J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.
Jong T; Li J; Morton DA; Zhou QT; Larson I
J Pharm Sci; 2016 Mar; 105(3):1156-63. PubMed ID: 26886330
[TBL] [Abstract][Full Text] [Related]
10. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
Yu J; Chan HK; Gengenbach T; Denman JA
Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
[TBL] [Abstract][Full Text] [Related]
11. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
12. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
[TBL] [Abstract][Full Text] [Related]
14. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
[TBL] [Abstract][Full Text] [Related]
15. Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
Kaewjan K; Srichana T
Pharm Dev Technol; 2016; 21(1):68-75. PubMed ID: 25331092
[TBL] [Abstract][Full Text] [Related]
16. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
Son YJ; Worth Longest P; Hindle M
Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
[TBL] [Abstract][Full Text] [Related]
18. Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend.
Wauthoz N; Hennia I; Ecenarro S; Amighi K
Int J Pharm; 2018 Dec; 553(1-2):47-56. PubMed ID: 30321640
[TBL] [Abstract][Full Text] [Related]
19. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
Jetzer MW; Schneider M; Morrical BD; Imanidis G
J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
[TBL] [Abstract][Full Text] [Related]
20. Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance.
Yang Y; Yang Z; Ren Y; Mei X
Drug Deliv; 2014 Sep; 21(6):480-6. PubMed ID: 24491208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
